The relative diagnostic sensitivity of different F‐wave parameters in various polyneuropathies

The relative diagnostic sensitivity of different F‐wave parameters in various polyneuropathies
复制标题

不同 F 波参数对各种多发性神经病的相对诊断敏感性

DOI:
--
复制
发表时间:
1992
期刊:
影响因子:
3.4
通讯作者:
R. Olney
R. Olney
中科院分区:
医学3区
文献类型:
--
作者:
J. Fraser;R. Olney

文献摘要

被引文献

相似文献

我们研究了70名对照组和75名各种多发性神经病患者正中神经和尺神经中F波的最小潜伏期、持续时间和时间离散度。在所有多发性神经病患者中,最短潜伏期延长是最常见的F波异常。在格林-巴利综合征(GBS)和慢性炎症性脱髓鞘性多发性神经病(CIDP)中,F反应持续时间降低或缺失对最小潜伏期延长的敏感性与之相当,而时间离散性仅在CIDP中具有类似的敏感性。获得的F反应持续性降低,以及复合肌肉动作电位波幅低的神经中没有F反应,这些都是非特异性的发现。F波检查通常在评估疑似患有多发性神经病的患者时提供有用的附加信息。在轴索多发性神经病患者中,我们发现F波研究在识别运动轴突生理性异常方面明显比标准运动传导研究更敏感。此外,在获得性多发性神经病患者中,发现最短潜伏期显著延长,或在CMAP波幅正常的神经中没有F-反应,对脱髓鞘的存在具有高度的特异性。©1992 John Wiley父子公司
We studied F‐wave minimum latency, persistence, and chronodispersion in the median and ulnar nerves of 70 controls and 75 patients with various polyneuropathies. Prolonged minimum latency was the most frequent F‐wave abnormality in all groups of patients with polyneuropathy. The finding of decreased persistence or absence of F‐responses was comparable in sensitivity to prolonged minimum latency in Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), whereas chronodispersion had a comparable sensitivity only in CIDP. Decreased persistence of obtained F‐responses, and the absence of F‐responses in nerves with low compound muscle action potential amplitudes, were nonspecific findings. F‐wave studies often provide useful additional information in the evaluation of patients suspected of having a polyneuropathy. In patients with axonal polyneuropathies, we found that F‐wave studies are significantly more sensitive than standard motor conduction studies in identifying physiological abnormalities of motor axons. Furthermore, in a patient with an acquired polyneuropathy, the finding of markedly prolonged minimum latency, or the absence of F‐responses in nerves with normal CMAP amplitude, is highly specific for the presence of demyelination. © 1992 John Wiley & Sons, Inc.